

# **Name: Clinical oncology basics / Podstawy onkologii klinicznej**

Lecture language: **English**

Semester: **winter 2022**

Responsible teacher: **Monika Dudzisz – Śledź, PhD**

## **Module summary:**

This module provides a foundation for providing care to patients experiencing a cancer diagnosis, treatment complications, or trouble coping. It covers a range of basic topics, from cancer biology, treatments, symptom management and immunooncology. The course aims to provide orientation to the guiding principles of multidisciplinary oncological management.

## **Module content**

### **Lectures (10h) / Mondays 8.00 am**

1. Biology of cancer (2h) – **24.10.2022**
2. Cancer staging and treatment efficacy assessment (2h) – **07.11.2022**
3. Cancer treatment and toxicity management and assessment (2h) – **21.11.2022**
4. Immunooncology and immunotherapy (2h) – **05.12.2022**
5. Cancer related symptoms management (2h) – **19.12.2022**

## **Teaching methods and techniques:**

- **Lectures:** The topics presented in the lecture are shown in the form of a multimedia (powerpoint) presentation in Teams application

## **The conditions obtaining the acknowledge for the classes, including the rules of exam retaking, as well as the conditions of admission to the exam:**

In order to pass the subject a positive grade must be obtained from a test on the entirety of the theoretical material.

## **Participation rules in classes:**

– Attendance is mandatory: **Yes**

– Participation rules in classes: Students that take part in the classes will learn subsequent topics according to the syllabus of the class. Students should systematically ask questions. Recording of the lecture can only be done with the approval of the lecturer.

## **The method and mode of making up for the absences**

If the requirements are met for obtaining a passing grade, the student is required to independently catch up with the material. If he/she fails to do so, he/she must obtain a positive grade on a test that pertains to the material discussed during his absence.

## **Prerequisites and additional requirements:**

Without requirements

**Recommended literature and teaching resources:**

1. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res*. 2009;15(23):7412-7420. doi:10.1158/1078-0432.CCR-09-1624
2. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer*. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
3. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. *CA Cancer J Clin*. 2017;67(2):93-99. doi:10.3322/caac.21388
4. CTCAE v 5.0  
[https://ctep.cancer.gov/protocoldevelopment/electronic\\_applications/docs/CTCAE\\_v5\\_Quick\\_Reference\\_5x7.pdf](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf)
5. Fabi A, Bhargava R, Fatigoni S, et al. Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment [published online ahead of print, 2020 Mar 12]. *Ann Oncol*. 2020;S0923-7534(20)36077-4. doi:10.1016/j.annonc.2020.02.016
6. Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2018;29 Suppl 4:iv166-iv191. doi:10.1093/annonc/mdy152
7. Li B, Chan HL, Chen P. Immune Checkpoint Inhibitors: Basics and Challenges. *Curr Med Chem*. 2019;26(17):3009-3025. doi:10.2174/0929867324666170804143706
8. Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines [published correction appears in *Ann Oncol*. 2018 Oct 1;29(Suppl 4):iv271] [published correction appears in *Ann Oncol*. 2018 Oct;29 Suppl 4:iv271]. *Ann Oncol*. 2018;29(Suppl 4):iv96-iv110. doi:10.1093/annonc/mdx758
9. Haanen JBAG, Carbone F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in *Ann Oncol*. 2018 Oct 1;29(Suppl 4):iv264-iv266] [published correction appears in *Ann Oncol*. 2018 Oct;29 Suppl 4:iv264-iv266]. *Ann Oncol*. 2017;28(suppl\_4):iv119-iv142. doi:10.1093/annonc/mdx225
10. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2016;27(suppl 5):v111-v118. doi:10.1093/annonc/mdw325
11. ESMO HANDBOOK OF IMMUNO-ONCOLOGY
12. ESMO HANDBOOK OF CANCER DIAGNOSIS AND TREATMENT EVALUATION, 2ND EDITION
13. ESMO HANDBOOK OF ADVANCED CANCER CARE
14. American Cancer Society webpage, cancer staging:  
<https://www.cancer.org/treatment/understanding-your-diagnosis/staging.html>

**Additional information:**

None